Bioton S.a. (BIO.WA)

Bioton S.a. (BIO.WA) — VMCI valuation read

BIO.WA screens at VMCI 42/100, a 9-point gap below the Healthcare sector median (50). For a mid-cap Bioton S.a. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

BIO.WA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: BIO.WA trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.5x leaves covenant headroom, which sets the rate-cycle exposure for Bioton S.a..

BIO.WA fell 0.7% over the trailing 7 days, with a -6.5% read on a 30-day basis.